Elocom and Insulin degludec and liraglutide Subcutaneous
Determining the interaction of Elocom and Insulin degludec and liraglutide Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using liraglutide together with insulin degludec can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: mometasone topical
Brand name: Elocon
Synonyms: Mometasone topical, Mometasone (Topical)
Generic Name: insulin degludec / liraglutide
Brand name: Xultophy
Synonyms: Insulin degludec and liraglutide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Elocom-Insulin degludec Subcutaneous
- Elocom-Insulin detemir
- Elocom-Insulin Detemir (Cartridges and Prefilled Syringes)
- Elocom-Insulin Detemir (Vials)
- Elocom-Insulin detemir Subcutaneous
- Elocom-Insulin glargine
- Insulin degludec and liraglutide Subcutaneous-Elocon
- Insulin degludec and liraglutide Subcutaneous-Elocon Cream
- Insulin degludec and liraglutide Subcutaneous-Elocon Lotion
- Insulin degludec and liraglutide Subcutaneous-Elocon topical
- Insulin degludec and liraglutide Subcutaneous-Eloctate
- Insulin degludec and liraglutide Subcutaneous-Eloctate with Fc Fusion Protein recombinant